Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,205,592
  • Shares Outstanding, K 1,266,455
  • Annual Sales, $ 22,127 M
  • Annual Income, $ 5,455 M
  • 60-Month Beta 1.10
  • Price/Sales 3.73
  • Price/Cash Flow 8.90
  • Price/Book 3.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 1.67
  • Number of Estimates 7
  • High Estimate 1.76
  • Low Estimate 1.61
  • Prior Year 1.70
  • Growth Rate Est. (year over year) -1.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.89 +6.60%
on 10/03/19
67.01 -3.14%
on 09/20/19
-0.81 (-1.23%)
since 09/18/19
3-Month
60.89 +6.60%
on 10/03/19
68.40 -5.10%
on 07/29/19
-2.30 (-3.42%)
since 07/18/19
52-Week
60.32 +7.61%
on 12/26/18
74.80 -13.22%
on 10/19/18
-9.26 (-12.48%)
since 10/18/18

Most Recent Stories

More News
Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?

During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.

GILD : 64.91 (-0.49%)
ACHN : 6.09 (-1.77%)
AMGN : 202.72 (-0.41%)
ALXN : 98.41 (-1.58%)
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.

MRK : 84.68 (+1.05%)
GILD : 64.91 (-0.49%)
ALXN : 98.41 (-1.58%)
GLPG : 157.02 (-3.67%)
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

PFE : 36.46 (unch)
MRK : 84.68 (+1.05%)
NVS : 86.88 (-0.40%)
GILD : 64.91 (-0.49%)
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $65.23, marking a -0.18% move from the previous day.

GILD : 64.91 (-0.49%)
Impel NeuroPharma Announces Appointment Of Diane Wilfong To Board Of Directors

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with...

GILD : 64.91 (-0.49%)
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company...

PFE : 36.46 (unch)
LLY : 108.64 (+0.17%)
AMGN : 202.72 (-0.41%)
GILD : 64.91 (-0.49%)
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GILD : 64.91 (-0.49%)
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth

RHHBY : 36.8100 (+0.68%)
GILD : 64.91 (-0.49%)
AMGN : 202.72 (-0.41%)
BIIB : 220.06 (-2.46%)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.53% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $64.61 to a high of $65.59. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of...

GILD : 64.91 (-0.49%)
SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 1.53% Gain

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $64.61 to a high of $65.59. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of...

GILD : 64.91 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 66.10
1st Resistance Point 65.51
Last Price 64.91
1st Support Level 64.26
2nd Support Level 63.60

See More

52-Week High 74.80
Fibonacci 61.8% 69.27
Fibonacci 50% 67.56
Fibonacci 38.2% 65.85
Last Price 64.91
52-Week Low 60.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar